Novo Nordisk
414,3
DKK
+2,68 %
Mindre end 1K følgere
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+2,68%
-13,8%
-33,44%
-33,63%
-47,18%
-53,27%
+4,97%
+86,01%
+33.177,11%
Novo Nordisk er producent af insulin til behandling af diabetes. Ud over specialkundskaben inden for diabetes producerer virksomheden lægemidler til hormonbehandling, samt produkter til hæmofili og blødningsforstyrrelser. Produkterne findes på det globale marked og sælges under separate mærker. Virksomheden blev oprindeligt grundlagt i 1923 og har hovedsæde i Bagsværd.
Læs mereMarkedsværdi
1,85 bio. DKK
Aktieomsætning
1,39 mia. DKK
Omsætning
290,4 mia.
EBIT %
44,19 %
P/E
18,28
Udbytteafkast, %
2,75 %
Finanskalender
7.5
2025
Delårsrapport Q1'25
6.8
2025
Delårsrapport Q2'25
5.11
2025
Delårsrapport Q3'25
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Resolutions from the Annual General Meeting of Novo Nordisk A/S
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Aktier i Vælten – Hvordan gik det med de regnskabsaktuelle C25-selskaber?
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk files annual report with the SEC
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
